Suppr超能文献

新型抗感染药物的匮乏:步入后抗生素时代?

Lack of new antiinfective agents: Passing into the pre-antibiotic age?

作者信息

Brandenburg Klaus, Schürholz Tobias

机构信息

Klaus Brandenburg, Forschungszentrum Borstel, Leibniz-Zentrum für Medizin und Biowissenschaften, D-23845 Borstel, Germany.

出版信息

World J Biol Chem. 2015 Aug 26;6(3):71-7. doi: 10.4331/wjbc.v6.i3.71.

Abstract

The lack of newly developed antibiotics, together with the increase in multi-resistance of relevant pathogenic bacteria in the last decades, represents an alarming signal for human health care worldwide. The number of severely infected persons increases not only in developing but also in highly industrialized countries. This relates in first line to the most severe form of a bacterial infection, sepsis and the septic shock syndrome, with high mortality on critical care units. No particular anti-sepsis drug is available, and the therapy with conventional antibiotics more and more fails to provide a survival benefit. Due to the fact that the pharmaceutical industry has withdrawn to a high degree from the development of anti-infectious agents, a huge challenge for health care is approaching in the 21(st) century. In this article, these problems are outlined and possible alternatives are presented which may be helpful to solve the problem.

摘要

在过去几十年中,新开发抗生素的缺乏,加上相关病原菌多重耐药性的增加,对全球人类医疗保健而言是一个警示信号。不仅在发展中国家,而且在高度工业化国家,严重感染患者的数量都在增加。这首先与细菌感染最严重的形式——败血症和脓毒性休克综合征有关,在重症监护病房死亡率很高。目前没有特效的抗败血症药物,使用传统抗生素进行治疗越来越无法带来生存获益。由于制药行业已在很大程度上退出抗感染药物的研发,21世纪医疗保健将面临巨大挑战。本文概述了这些问题,并提出了可能有助于解决该问题的替代方案。

相似文献

3
Sepsis Care Pathway 2019.2019年脓毒症护理路径
Qatar Med J. 2019 Nov 7;2019(2):4. doi: 10.5339/qmj.2019.qccc.4. eCollection 2019.
8
Current treatment of sepsis and endotoxaemia.脓毒症和内毒素血症的当前治疗方法。
Expert Opin Pharmacother. 2000 Sep;1(6):1203-17. doi: 10.1517/14656566.1.6.1203.
9
The challenges of multi-drug-resistance in hepatology.肝医学领域的多药耐药挑战。
J Hepatol. 2016 Nov;65(5):1043-1054. doi: 10.1016/j.jhep.2016.08.006. Epub 2016 Aug 17.
10
Sepsis and septic shock.脓毒症和脓毒性休克。
Schweiz Med Wochenschr. 1997 Mar 22;127(12):489-99.

引用本文的文献

3
Antimicrobial peptides - Advances in development of therapeutic applications.抗菌肽——治疗应用开发的进展。
Life Sci. 2020 Nov 1;260:118407. doi: 10.1016/j.lfs.2020.118407. Epub 2020 Sep 12.

本文引用的文献

1
Strategies to improve drug development for sepsis.改善脓毒症药物研发的策略。
Nat Rev Drug Discov. 2014 Oct;13(10):741-58. doi: 10.1038/nrd4368. Epub 2014 Sep 5.
5
New antiseptic peptides to protect against endotoxin-mediated shock.新型抗菌肽,预防内毒素介导的休克。
Antimicrob Agents Chemother. 2010 Sep;54(9):3817-24. doi: 10.1128/AAC.00534-10. Epub 2010 Jul 6.
6
Mechanisms of sepsis and insights from clinical trials.脓毒症的发病机制及临床试验的见解。
Drug Discov Today Dis Mech. 2007;4(2):83-93. doi: 10.1016/j.ddmec.2007.10.004.
7
[Severe sepsis--new therapeutic options].[严重脓毒症——新的治疗选择]
Internist (Berl). 2001 Dec;42(12):1619-20, 1623-30. doi: 10.1007/s001080170014.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验